BACKGROUND: Neoadjuvant chemotherapy (NAC) is commonly utilized to treat operable breast cancer. The purpose of this study was to review the findings of ultrasonography (US) and magnetic resonance (MR) imaging in patients treated with breast conservation surgery (BCS) after NAC with a focus on intrinsic subtypes. METHODS: Eighty-six patients underwent BCS after NAC. The tumors were classified into four subgroups by receptor status. US and MR were performed before and after NAC. The tumor diameters in US and MR after NAC were examined for correlations with pathological tumor distances in the specimens from BCS after NAC. RESULTS: The correlation coefficient (r) of US to pathological tumor size was 0.3 in all tumors, 0.6 in HER2-type tumors, and 0.7 in triple negative breast cancers (TNBC). The correlation coefficient of tumor size in MR to pathological tumor size was 0.9 in TNBC, and other correlations were not statistically significant. CONCLUSIONS: The correlation between tumor size in MR and pathological tumor size in triple negative breast cancers corresponded best. This information is one of the clues to selecting patients for BCS after NAC.
BACKGROUND: Neoadjuvant chemotherapy (NAC) is commonly utilized to treat operable breast cancer. The purpose of this study was to review the findings of ultrasonography (US) and magnetic resonance (MR) imaging in patients treated with breast conservation surgery (BCS) after NAC with a focus on intrinsic subtypes. METHODS: Eighty-six patients underwent BCS after NAC. The tumors were classified into four subgroups by receptor status. US and MR were performed before and after NAC. The tumor diameters in US and MR after NAC were examined for correlations with pathological tumor distances in the specimens from BCS after NAC. RESULTS: The correlation coefficient (r) of US to pathological tumor size was 0.3 in all tumors, 0.6 in HER2-type tumors, and 0.7 in triple negative breast cancers (TNBC). The correlation coefficient of tumor size in MR to pathological tumor size was 0.9 in TNBC, and other correlations were not statistically significant. CONCLUSIONS: The correlation between tumor size in MR and pathological tumor size in triple negative breast cancers corresponded best. This information is one of the clues to selecting patients for BCS after NAC.
Authors: Jennifer F De Los Santos; Alan Cantor; Keith D Amos; Andres Forero; Mehra Golshan; Janet K Horton; Clifford A Hudis; Nola M Hylton; Kandace McGuire; Funda Meric-Bernstam; Ingrid M Meszoely; Rita Nanda; E Shelley Hwang Journal: Cancer Date: 2013-02-21 Impact factor: 6.860
Authors: Rosalind P Candelaria; Roland L Bassett; William Fraser Symmans; Maheshwari Ramineni; Stacy L Moulder; Henry M Kuerer; Alastair M Thompson; Wei Tse Yang Journal: Oncologist Date: 2017-03-17
Authors: Jeon-Hor Chen; Shadfar Bahri; Rita S Mehta; Philip M Carpenter; Christine E McLaren; Wen-Pin Chen; Peter T Fwu; David J B Hsiang; Karen T Lane; John A Butler; Min-Ying Su Journal: J Surg Oncol Date: 2013-10-28 Impact factor: 3.454
Authors: M B I Lobbes; R Prevos; M Smidt; V C G Tjan-Heijnen; M van Goethem; R Schipper; R G Beets-Tan; J E Wildberger Journal: Insights Imaging Date: 2013-01-29
Authors: Michael L Marinovich; Petra Macaskill; Les Irwig; Francesco Sardanelli; Eleftherios Mamounas; Gunter von Minckwitz; Valentina Guarneri; Savannah C Partridge; Frances C Wright; Jae Hyuck Choi; Madhumita Bhattacharyya; Laura Martincich; Eren Yeh; Viviana Londero; Nehmat Houssami Journal: BMC Cancer Date: 2015-10-08 Impact factor: 4.430
Authors: M L Marinovich; P Macaskill; L Irwig; F Sardanelli; G von Minckwitz; E Mamounas; M Brennan; S Ciatto; N Houssami Journal: Br J Cancer Date: 2013-08-20 Impact factor: 7.640
Authors: Rita A Mukhtar; Christina Yau; Mark Rosen; Vickram J Tandon; Nola Hylton; Laura J Esserman Journal: Ann Surg Oncol Date: 2013-06-19 Impact factor: 5.344